Leukemia :: Oncaspar for Newly-Diagnosed Acute Lymphoblastic Leukemia
The Food and Drug Administration (FDA) today expanded the approved use of Oncaspar to include treating children and adults with newly diagnosed acute lymphoblastic leukemia (ALL) as part of a multiple drug chemotherapy regimen. FDA previously approved Oncaspar in 1994 only for patients with ALL who were unable to receive the cancer drug L-asparaginase because they were allergic to that drug.